Suppr超能文献

英国西米德兰兹郡遗传性代谢疾病的发病率。

The incidence of inherited metabolic disorders in the West Midlands, UK.

作者信息

Sanderson S, Green A, Preece M A, Burton H

机构信息

General Practice and Primary Care Research Unit, University of Cambridge, Cambridge, UK.

出版信息

Arch Dis Child. 2006 Nov;91(11):896-9. doi: 10.1136/adc.2005.091637. Epub 2006 May 11.

Abstract

BACKGROUND

Inherited metabolic disorders (IMDs) are a heterogeneous group of genetic conditions mostly occurring in childhood. They are individually rare but collectively numerous, causing substantial morbidity and mortality.

AIMS

To obtain up-to-date estimates of the birth prevalence of IMDs in an ethnically diverse British population and to compare these estimates with those of other published population-based studies.

METHODS

Retrospective data from the West Midlands Regional Diagnostic Laboratory for Inherited Metabolic Disorders (Birmingham, UK) for the 5 years (1999-2003) were examined. The West Midlands population of 5.2 million is approximately 10% of the UK population. Approximately 11% of the population of the region is from black and ethnic minority groups compared with approximately 8% for the the UK.

RESULTS

The overall birth prevalence was 1 in 784 live births (95% confidence interval (CI) 619 to 970), based on a total of 396 new cases. The most frequent diagnoses were mitochondrial disorders (1 in 4929; 95% CI 2776 to 8953), lysosomal storage disorders (1 in 5175; 95% CI 2874 to 9551), amino acid disorders excluding phenylketonuria (1 in 5354; 95% CI 2943 to 9990) and organic acid disorders (1 in 7962; 95% CI 3837 to 17 301). Most of the diagnoses (72%) were made by the age of 15 years and one-third by the age of 1 year.

CONCLUSIONS

These results are similar to those of the comparison studies, although the overall birth prevalence is higher in this study. This is probably due to the effects of ethnicity and consanguinity and increasing ascertainment. This study provides useful epidemiological information for those planning and providing services for patients with IMDs, including newborn screening, in the UK and similar populations.

摘要

背景

遗传性代谢疾病(IMDs)是一组异质性的遗传病症,大多在儿童期发病。它们单种疾病较为罕见,但总体数量众多,会导致较高的发病率和死亡率。

目的

获取英国不同种族人群中遗传性代谢疾病出生患病率的最新估计值,并将这些估计值与其他已发表的基于人群的研究结果进行比较。

方法

对西米德兰兹地区遗传性代谢疾病诊断实验室(英国伯明翰)1999年至2003年这5年的回顾性数据进行了研究。西米德兰兹地区有520万人口,约占英国人口的10%。该地区约11%的人口来自黑人和少数族裔群体,而英国这一比例约为8%。

结果

基于总共396例新病例,总体出生患病率为1/784活产儿(95%置信区间(CI)为619至970)。最常见的诊断疾病为线粒体疾病(1/4929;95%CI为2776至8953)、溶酶体贮积症(1/5175;95%CI为2874至9551)、不包括苯丙酮尿症的氨基酸疾病(1/5354;95%CI为2943至9990)和有机酸疾病(1/7962;95%CI为3837至17301)。大多数诊断(72%)在15岁时做出,三分之一在1岁时做出。

结论

尽管本研究中的总体出生患病率较高,但这些结果与比较研究的结果相似。这可能是由于种族和近亲结婚的影响以及确诊率的提高。本研究为英国及类似人群中为遗传性代谢疾病患者规划和提供服务(包括新生儿筛查)的人员提供了有用的流行病学信息。

相似文献

1
The incidence of inherited metabolic disorders in the West Midlands, UK.
Arch Dis Child. 2006 Nov;91(11):896-9. doi: 10.1136/adc.2005.091637. Epub 2006 May 11.
2
Incidence of inborn errors of metabolism in British Columbia, 1969-1996.
Pediatrics. 2000 Jan;105(1):e10. doi: 10.1542/peds.105.1.e10.
5
Screening for tyrosinaemia type I.
Arch Dis Child Fetal Neonatal Ed. 1996 May;74(3):F191-4. doi: 10.1136/fn.74.3.f191.
7
Inherited metabolic disorders in Turkish patients with autism spectrum disorders.
Autism Res. 2016 Feb;9(2):217-23. doi: 10.1002/aur.1507. Epub 2015 Jun 7.

引用本文的文献

1
Updated Gene Therapy for Renal Inborn Errors of Metabolism.
Genes (Basel). 2025 Apr 29;16(5):516. doi: 10.3390/genes16050516.
4
Nutritional Management of Patients with Inborn Errors of Metabolism.
Nutrients. 2024 Nov 30;16(23):4154. doi: 10.3390/nu16234154.
6
Estimating the sensitivity of genomic newborn screening for treatable inherited metabolic disorders.
Genet Med. 2025 Jan;27(1):101284. doi: 10.1016/j.gim.2024.101284. Epub 2024 Sep 28.
7
Outcome of Expanded Newborn Screening Among 194 000 Neonates at Northeast México.
Glob Pediatr Health. 2024 Sep 20;11:2333794X241280830. doi: 10.1177/2333794X241280830. eCollection 2024.
9
Exploring HLA-C methylation patterns and nutritional status in Kichwa mothers and infants from Tena, Ecuador.
Front Med (Lausanne). 2024 Aug 27;11:1356646. doi: 10.3389/fmed.2024.1356646. eCollection 2024.

本文引用的文献

1
Enzyme replacement therapy in mucopolysaccharidosis type I.
Acta Paediatr Suppl. 2005 Mar;94(447):58-60; discussion 57. doi: 10.1111/j.1651-2227.2005.tb02114.x.
2
Ashkenazi Jewish genetic disorders.
Fam Cancer. 2004;3(3-4):201-6. doi: 10.1007/s10689-004-9545-z.
5
Treatment of lysosomal storage disorders: cell therapy and gene therapy.
J Inherit Metab Dis. 2004;27(3):411-5. doi: 10.1023/B:BOLI.0000031170.69676.68.
6
Hematopoietic stem cell transplantation for mucopolysaccharidoses and leukodystrophies.
Klin Padiatr. 2004 May-Jun;216(3):163-8. doi: 10.1055/s-2004-822629.
9
Screening newborns for inborn errors of metabolism by tandem mass spectrometry.
N Engl J Med. 2003 Jun 5;348(23):2304-12. doi: 10.1056/NEJMoa025225.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验